DWTX
Dogwood Therapeutics, Inc.
Key Financials
Operating Income
$-27968445
↓ 128.7%
Net Income
$-34257370
↓ 177.4%
EPS (Diluted)
$-7.13
↑ 43.1%
Total Liabilities
$15.3M
↓ 49.1%
Total Assets
$90.2M
↓ 4.4%
Cash & Equivalents
$6.5M
↓ 56.1%
Operating Cash Flow
$-15618651.00
↓ 77.7%
Shareholders' Equity
$74.9M
↑ 839.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| ARS | 4/27/2026 | View on SEC |
| DEF 14A | 4/27/2026 | View on SEC |
| PRE 14A | 4/17/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 10-K | 3/18/2026 | View on SEC |
| 8-K | 3/18/2026 | View on SEC |
| 8-K | 3/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DWTX |
| Company Name | Dogwood Therapeutics, Inc. |
| CIK | 1818844 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 8666208655 |